Important New Information!
CASP Monitoring Device testing has a 99.17% accuracy correlation to sphygmomanometer (manual or automated) or the “Gold Standard” a catheterization (angiogram) which is much more expensive and invasive. CASP Monitoring Device is 100% non invasive, FDA Approved, and reimbursable by Insurance and Medicare. The test takes approximately 3-5 minutes to administer.
Understanding treatment protocols have not changed; implementing the CASP Monitoring Device validates and compliments the current triage for hypertension measurement by how it affects the largest artery of the body the aorta (the Gold Standard) as well as the brachial parameter.
If the triage (meds) does not lower the CASP, one of two things need to happen:
1) The patient needs to be on a different mix of medications to lower the CASP.
2) The patient needs to take their medication.
“Measuring CASP is just going one layer deeper to validate the current hypertensive treatment and how it affects the largest artery in the body the aorta.”